Kane Biotech Inc.
KNBIF
$0.03
$0.00-11.59%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 141.30% | 1,344.70% | 1,281.40% | 210.74% | 160.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.30% | 1,344.70% | 1,281.40% | 210.74% | 160.69% |
| Cost of Revenue | 354.50% | 3,358.41% | 2,919.86% | 218.03% | 154.13% |
| Gross Profit | 2.44% | 612.46% | 690.86% | 204.15% | 165.88% |
| SG&A Expenses | -30.74% | 21.12% | 26.29% | 291.74% | 166.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.10% | 55.82% | 63.76% | 630.07% | 301.66% |
| Operating Income | 38.80% | 2.44% | -9.64% | -56.49% | -77.09% |
| Income Before Tax | 41.33% | 17.84% | 3.25% | -23.19% | -44.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.48% | 43.40% | 30.96% | -23.19% | -44.30% |
| Earnings from Discontinued Operations | -111.70% | 3,258.52% | 2,042.75% | 2,611.65% | 3,755.94% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.27% | 220.19% | 219.94% | 231.00% | 222.17% |
| EBIT | 38.80% | 2.44% | -9.64% | -56.49% | -77.09% |
| EBITDA | 39.39% | 1.30% | -10.66% | -57.98% | -79.66% |
| EPS Basic | -161.92% | 220.67% | 216.44% | 226.23% | 214.54% |
| Normalized Basic EPS | 50.52% | 27.68% | 11.52% | -21.28% | -44.78% |
| EPS Diluted | -223.13% | 168.17% | 163.08% | 162.45% | 161.78% |
| Normalized Diluted EPS | 49.20% | 30.46% | 14.20% | -18.84% | -42.75% |
| Average Basic Shares Outstanding | 11.78% | 7.44% | 5.34% | 6.56% | 6.24% |
| Average Diluted Shares Outstanding | 9.74% | 8.00% | 5.99% | 7.17% | 6.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |